In Part B, there were two PRs in patients with V600E BRAF-mutated melanoma (primary tumour on the right leg, KRAS-WT, AKT-positive, PTEN-positive; primary tumour on right inguinal node, other mutation status unknown due to lack of tissue for testing), who had responses for >40 cycles (36.8 months), and one PR in a patient with BRAF-WT, KRAS-WT melanoma (primary tumour on nose) who had a response for more than 2 cycles (3.0 months); all three patients were receiving E6201 320 mg/m2 once-weekly. This evidence concerns the gene BRAF and neoplasm.